AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCL is a good fit for your portfolio.
News
-
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
-
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
-
AbCellera Reports Q1 2024 Business Results
-
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
Trading Information
- Previous Close Price
- $3.10
- Day Range
- $3.15–3.28
- 52-Week Range
- $2.65–7.89
- Bid/Ask
- $3.22 / $3.26
- Market Cap
- $958.62 Mil
- Volume/Avg
- 693,616 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 586
- Website
- https://www.abcellera.com
Comparables
Valuation
|
Metric
|
ABCL
|
NYKD
|
AURA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.85 | 2.79 | 2.46 |
Price/Sales | 26.45 | 40.25 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ABCL
NYKD
AURA
Financial Strength
|
Metric
|
ABCL
|
NYKD
|
AURA
|
|---|---|---|---|
Quick Ratio | 7.31 | 8.43 | 20.99 |
Current Ratio | 7.76 | 8.43 | 21.97 |
Interest Coverage | — | — | — |
Quick Ratio
ABCL
NYKD
AURA
Profitability
|
Metric
|
ABCL
|
NYKD
|
AURA
|
|---|---|---|---|
Return on Assets (Normalized) | −5.95% | −18.26% | −33.27% |
Return on Equity (Normalized) | −7.61% | −23.64% | −38.10% |
Return on Invested Capital (Normalized) | −10.11% | −26.98% | −37.96% |
Return on Assets
ABCL
NYKD
AURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hkbqxyxvmh | Fdm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rlfbmnml | Tlnxkf | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zxllqmvnd | Wdpbvr | $118.7 Bil | |||
| Moderna Inc
MRNA
| Lmcvnprg | Jkjp | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qpkjjpbxn | Vklyhyk | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lfwmcvtd | Twk | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Jvgbtgw | Hytp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bgvqmtwv | Scvfhy | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Plsyrgcqg | Smhww | $15.0 Bil | |||
| Incyte Corp
INCY
| Ttxnyrbd | Szfjmw | $13.5 Bil |